$0.05 per share earnings expected for Zynex, Inc. (NASDAQ: ZYXI) this quarter
Wall Street brokers expect Zynex, Inc. (NASDAQ:ZYXI – Get Rating) to post earnings of $0.05 per share for the current fiscal quarter, according to Zacks. Three analysts released earnings estimates for Zynex, with the lowest EPS estimate of $0.04 and the highest estimate of $0.06. Zynex posted earnings per share of ($0.02) in the same quarter last year, suggesting a positive growth rate of 350% year over year. The company is expected to release its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect Zynex to report annual earnings of $0.50 per share for the current year, with EPS estimates ranging from $0.43 to $0.55. For next year, analysts expect the company to post earnings of $0.72 per share, with EPS estimates ranging from $0.55 to $0.90. Zacks EPS averages are an average average based on a survey of research analysts who cover Zynex.
Zynex (NASDAQ:ZYXI – Get Rating) last announced its results on Thursday, February 24. The company reported earnings per share of $0.23 for the quarter, beating consensus analyst estimates of $0.19 by $0.04. Zynex had a net margin of 13.13% and a return on equity of 29.01%.
Several research analysts have commented on ZYXI shares. HC Wainwright lowered its price target on Zynex shares from $22.00 to $20.00 and set a “buy” rating for the company in a Friday, February 25 report. Zacks Investment Research downgraded Zynex shares from a “hold” rating to a “sell” rating in a Friday, February 25 research report. Piper Sandler reduced her target price on Zynex shares from $13.00 to $7.00 in a Friday, Feb. 25 research report. TheStreet downgraded Zynex shares from a “b-” to a “c+” rating in a Monday, Dec. 20 research note. Finally, B. Riley lowered his price target on Zynex shares from $15.50 to $10.00 and set a “buy” rating for the company in a Monday, Feb. 28 research note. One analyst rated the stock with a sell rating, one gave the stock a hold rating, and three gave the stock a buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.70.
Shares of Zynex opened at $5.98 on Wednesday. The company has a market capitalization of $228.78 million, a P/E ratio of 13.62 and a beta of 0.93. The company has a debt ratio of 0.01, a quick ratio of 5.90 and a current ratio of 6.79. The company has a fifty-day moving average of $6.83 and a 200-day moving average of $10.17. Zynex has a fifty-two week low of $4.97 and a fifty-two week high of $16.26.
Several institutional investors have recently increased or reduced their stake in ZYXI. California State Teachers Retirement System increased its stake in Zynex by 4.2% during the third quarter. California State Teachers Retirement System now owns 27,944 shares of the company worth $318,000 after purchasing 1,133 additional shares during the period. The Alaska State Department of Revenue increased its holdings of Zynex stock by 8.7% in Q3. The Alaska State Department of Revenue now owns 14,678 shares of the company valued at $167,000 after buying 1,180 more shares last quarter. Juncture Wealth Strategies LLC increased its stake in Zynex by 5.4% in the fourth quarter. Juncture Wealth Strategies LLC now owns 24,586 shares of the company worth $245,000 after purchasing an additional 1,260 shares during the period. Northern Trust Corp increased its stake in Zynex by 0.7% in the fourth quarter. Northern Trust Corp now owns 227,778 shares of the company worth $2,271,000 after purchasing an additional 1,608 shares during the period. Finally, Connors Investor Services Inc. increased its stake in Zynex by 9.2% during the 4th quarter. Connors Investor Services Inc. now owns 21,420 shares of the company worth $214,000 after purchasing an additional 1,800 shares during the period. 27.23% of the shares are currently held by institutional investors and hedge funds.
Zynex Company Profile (Get a rating)
Zynex, Inc engages in the design, manufacture and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company is also developing a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is based in Englewood, CO.
Get a Free Copy of Zacks Research Report on Zynex (ZYXI)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Zynex right now?
Before you consider Zynex, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Zynex wasn’t on the list.
While Zynex currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here